Dianthus Therapeutics, Inc. (DNTH) Market Cap & Valuation Ratios
Dianthus Therapeutics, Inc. (DNTH) has a market cap of $4.3B and a price-to-sales ratio of 2255.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNTHDianthus Therapeutics, Inc.Follow DNTH — free
—
Price chart with a free account
- Market cap
- 4.3B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| DNTH | 4.3 | — | — | — | -3.6% | -61% | — | -32% |
| SRRK | 5.1 | — | — | — | -5.9% | — | — | -568% |
| ERAS | 5.0 | — | — | — | -1.9% | — | — | -97% |
| DFTX | 4.8 | — | — | — | -3.5% | — | — | -92% |
| CRSP | 4.8 | — | 223.8 | — | -7.8% | -65% | — | -30% |
| TVTX | 4.7 | — | 8.5 | 219.5 | 2.0% | +77% | -7% | -8% |
| GOSS | 4.6 | — | 86.3 | — | -3.5% | +32% | -312% | — |
| EWTX | 4.3 | — | — | — | -3.7% | — | — | -48% |
| RLAY | 4.0 | — | 373.2 | — | -5.3% | +24% | — | -47% |
| TNGX | 3.9 | — | 54.3 | — | -3.7% | +121% | -253% | -35% |
| ARQT | 3.9 | 148.6 | 8.2 | 103.9 | 1.0% | +76% | 7% | 14% |
| Median of these 10 | 148.6 | 70.3 | 161.7 | -3.6% | +54% | -130% | -47% |
.
Growth vs. price
each dot a company · hover or tap for valuesDianthus Therapeutics, Inc. — questions
- What is Dianthus Therapeutics, Inc.'s market cap?
- $4.3B.
- What is Dianthus Therapeutics, Inc.'s price-to-sales ratio?
- 2255.6.
Every figure on this page comes from Dianthus Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.